Search results
Results from the WOW.Com Content Network
Chest cold: Figure A shows the location of the lungs and bronchial tubes. Figure B is an enlarged view of a normal bronchial tube. Figure C is an enlarged view of a bronchial tube with bronchitis. Specialty: Pulmonology: Symptoms: Cough with sputum, wheezing, shortness of breath, fever, chest discomfort [1] [2] Duration: Up to 6 weeks [3] Causes
The infection then makes its way down to the bronchi. Symptoms include coughing up sputum, wheezing, shortness of breath, and chest pain. Bronchitis can be acute or chronic. [1] Acute bronchitis usually has a cough that lasts around three weeks, [4] and is also known as a chest cold. [5] In more than 90% of cases, the cause is a viral infection ...
Wheezing that gets worse. Fast breathing. Coughing. Chest tightness that gets worse. Inability to breathe when lying down. Trouble walking and talking. Sweating. Fast heart rate. Confusion ...
A routine chest X-ray is not always necessary for people who have symptoms of a lower respiratory tract infection. [4] Influenza affects both the upper and lower respiratory tracts. [citation needed] Antibiotics are the first line treatment for pneumonia; however, they are neither effective nor indicated for parasitic or viral infections. Acute ...
The type of cough you have is a clue to what's causing it: A wet cough (the type that brings up phlegm or mucus) is often a sign of a lower respiratory infection.
A postinfectious cough is a lingering cough that follows a respiratory tract infection, such as a common cold or flu and lasting up to eight weeks. Postinfectious cough is a clinically recognized condition represented within the medical literature.
Bronchiolitis obliterans results in worsening shortness of breath, wheezing, and a dry cough.The symptoms can start gradually, or severe symptoms can occur suddenly. [9] [10] These symptoms represent an obstructive pattern that is non-reversible with bronchodilator therapy, and need to be related to various lung insults. [11]
The FDA's decision gives some breathing room to rival GSK's chronic cough treatment camlipixant, which is in late-stage development with anticipated regulatory approval and launch in 2026.